1. 2022-RA-276-ESGO Value of surgical cytoreduction for subsequent ovarian cancer relapse in patients previously treated with chemotherapy alone at 1st-relapse: a subanalysis of the DESKTOP III/ENGOT-ov20 trial. (20th October 2022) Authors: Fotopoulou, Christina; Sehouli, Jalid; Vergote, Ignace; Reuss, Alexander; Leheurteur, Marianne; Hilpert, Felix; Savoye, Aude-Marie; Greggi, Stefano; Vernersson, Johanna; Resch, Benoît; Gatineau, Michel; Levêque, Jean; Zang, Rongyu; Jensen, Pernille T; Kim, Jae W; Santiago, Domingo; Raspagliesi, F... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 388 Efficacy of individualised starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator assessment (IA) in newly diagnosed advanced ovarian cancer (OC) patients. (4th December 2020) Authors: Peen, Ulla; Graybill, Whitney; González-Martin, Antonio; O'malley, David; Baurain, Jean-François; Prendergast, Emily; Follana, Philippe; Braicu, Elena I; Gupta, Divya; Monk, Bradley J Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 4 Page Start: A90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Issue 10 (October 2019) Authors: Mirza, Mansoor Raza; Åvall Lundqvist, Elisabeth; Birrer, Michael J; dePont Christensen, Rene; Nyvang, Gitte-Bettina; Malander, Susanne; Anttila, Maarit; Werner, Theresa L; Lund, Bente; Lindahl, Gabriel; Hietanen, Sakari; Peen, Ulla; Dimoula, Maria; Roed, Henrik; Ør Knudsen, Anja; Staff, Synnöve; ... Journal: Lancet oncology Issue: Volume 20:Issue 10(2019) Page Start: 1409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗